摘要
[目的]观察静脉化疗辅助参麦注射液治疗晚期非小细胞肺癌的临床疗效。[方法]将121例Ⅲ～Ⅳ期非小细胞肺癌患者随机分为治疗组和对照组;化疗方案均选用非小细胞肺癌一线化疗方案TP、GP和NP中的一种,治疗组同时静脉滴注参麦注射液;主要观察指标为:卡氏(KPS)评分、骨髓抑制情况、中医症状积分及近期疗效。[结果]治疗组KPS提高例数多于对照组,下降例数少于对照组,均具有统计学差异;中医症状改善情况,治疗组好于对照组;可测病灶近期疗效对比,两组无明显统计学差异;骨髓抑制方面,治疗组的0～Ⅱ度白细胞减少发生率高于对照组,而Ⅲ～Ⅳ度白细胞减少发生率小于对照组,均有显著统计学差异。[结论]参麦注射液对改善晚期非小细胞肺癌的生存质量、临床症状,缓解骨髓抑制有一定作用。
[Objective] To observe the clinical effect of vein chemotherapy assisting Shen-Mai Injection on advanced NSCLC. [Method] Randomly divide 121 cases of NSCLC in Ⅲ-Ⅳ stage into treatment group and control group;the chemotherapy is chosen from TP, GP and NP;meanwhile, the treatment group takes Shen-Mai Injection by vein drip;mainly observe KPS score, bone marrow in hibition,TCM symptoms integral and the cure effect in the near future. [Result] For the treatment group,the cases with increased KPS were more than control one,the decreased cases less than control one, both with statistical difference;for TCM symptoms improvement, the treatment group was better than control one;for the comparison of cure effect of measurable focus in the near future, there＇s no marked statistical difference between both groups;on bone marrow inhibition, the leucocyte reduction rate at 0-11 degree of the treatment group was more than control one,while that at Ⅲ-Ⅳ less than control one,all with statistical difference. [Conclusion] Shen-Mai Injection has definite function in improving life quality, relieving clinical symptoms and bone marrow inhibition to NSCLC in advanced stage.
出处
《浙江中医药大学学报》
CAS
2009年第1期95-96,共2页
Journal of Zhejiang Chinese Medical University
